Abstract #2165
Gadoxetate contrast kinetics are altered in rat liver by a peptide deformylase inhibitor known to induce phospholipidosis
Stephen Clark Lenhard 1 , Mary Rambo 2 , Ciara Rodgers 2 , Mark Burgert 2 , Lindsey Webster 3 , Richard Peterson 3 , Richard Miller 3 , and Beat Jucker 2
1
GlaxoSmithKline, King of Prussia, PA, United
States,
2
GlaxoSmithKline,
PA, United States,
3
GlaxoSmithKline,
NC, United States
Phospholipidosis (PLD) is a generalized condition in
humans and animals characterized by an intracellular
accumulation of phospholipids. Using a clinically
available liver specific MRI contrast agent (Eovist;Gadoxetate),
hepatobiliary Dynamic Contrast Enhanced MRI (DCE-MRI)
was performed to determine if Gadoxetate kinetic changes
could be detected with a compound known to induce PLD.
Gadoxetate DCE MRI of liver function may be a useful
pre-clinical technique to assess hepatic functional
consequences of PLD in vivo to support drug development
decisions for compounds found to induce PLD.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
